Skip to content

Changed date for Annual General Meeting in AcuCort

AcuCort AB (publ) (Spotlight Stock Market: ACUC) announces that the Annual General Meeting 2022 will be held on 4 May 2022. According to previously published information, the Annual General Meeting was planned to be held on 5 May 2022. AcuCort will publish a notice to the Annual General Meeting four weeks prior to 4 May 2022 at the latest.

The information was submitted for publication, through the agency of the contact person below, on March 23, 2022.

For more information, please contact:
Jonas Jönmark, CEO, AcuCort AB
Telephone: + 46 (0)70 365 5400
Email: jonas.jonmark@acucort.se

About AcuCort AB (publ)
AcuCort has developed and commercializes ISICORT®, a new fast-dissolving oral film to put on the tongue, based on a well-known cortisone substance – dexamethasone. ISICORT® is a smart product in a new, innovative, patented, and user-friendly dosage form primarily for the treatment of severe and acute allergic reactions, croup in children and chemotherapy induced nausea and vomiting (CINV). A national application was approved by the Swedish Medical Products Agency (MPA) in October 2020. In February 2021, ISICORT® was granted an additional indication – the treatment of COVID-19 patients who need supplemental oxygen treatment. Altogether, this strengthens the company’s assessment that the time to commercialization of ISICORT® may be relatively short. AcuCort (ticker: ACUC) is listed on the Spotlight Stock Market in Sweden. Please visit www.acucort.com.